Newsroom | 469 results

ZUG, Switzerland--(BUSINESS WIRE)--Bprotocol Foundation, a non-profit foundation dedicated to promoting the development and adoption of the Bancor Protocol, and LocalCoin Ltd. (“LocalCoin”), the original developer of the Bancor Protocol, today announced that they have filed a lawsuit in the United States District Court for the Southern District of New York (the “Court”) against Uniswap Labs and Uniswap Foundation (collectively, “Uniswap”) for infringing Bancor patents directed to smart contract...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated...

ALBANY, N.Y.--(BUSINESS WIRE)--Soluna Holdings, Inc. (“Soluna” or the “Company”) (NASDAQ: SLNH), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, announced its financial results for the quarter year ended March 31, 2025. “Our outlook shines brighter with expanding project development at Projects Rosa, Ellen, and Hedy. First quarter results reflect operational stamina amidst challenges from market headwinds, commercial model shifts, weather...

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the Europea...

DUBLIN--(BUSINESS WIRE)--The "Managing Information Flows for IP (Intellectual Property) Purposes: Trade Secrets Training Course" conference has been added to ResearchAndMarkets.com's offering. This practical one-day course will enhance your knowledge of the principles and practice of information management in IP transactions, with a special focus on trade secrets. Safeguarding trade secrets is essential for maintaining a company’s competitive edge, ensuring financial stability, fostering innova...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 計畫更名為BeOne Medicines Ltd.的全球性腫瘤公司BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235)今日宣布，美國專利商標局(USPTO)做出最終書面決定，判定BeiGene在授權後複審(PGR)程序中提出質疑的Pharmacyclics LLC (Pharmacyclics)美國專利號11,672,803（‘803專利）中的所有權利主張均屬無效。 2023年11月1日，對於Pharmacyclics就BRUKINSA® (zanubrutinib)提起的針對BeiGene的專利侵權訴訟，BeiGene向USPTO遞交了一份PGR請願書，對‘803專利的某些權利主張的有效性提出質疑。2024年5月1日，USPTO核准了BeiGene啟動PGR的請願書。USPTO的最終書面決定可由Pharmacyclics提出上訴。 BeiGene總法律顧問Chan Lee對該裁定發表評論稱：「我們很高興USPTO判定‘803專利中所有被質疑的權利主張無效。今天...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa internacional de oncologia que pretende mudar seu nome para BeOne Medicines Ltd., anunciou hoje que a Agênica de Patentes e Marcas dos EUA (USPTO) emitiu uma Decisão Final por Escrito invalidando todas as reivindicações da Patente dos EUA nº 11.672.803 da Pharmacyclics LLC (Pharmacyclics) (a patente '803) que foram contestadas pela BeiGene em um processo de revisão pós-concessão (PGR). Em 1...

カリフォルニア州サン・カルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルながん領域専門の製薬企業であるベイジーン（NASDAQ：ONC、HKEX：06160、SSE：688235）（BeOne Medicines Ltd.へ社名変更予定）は、米国特許商標庁（USPTO）が、Pharmacyclics LLC（Pharmacyclics）が主張する米国特許第11,672,803号（ 「803号特許」 ）のすべての請求項について無効とする最終決定を下したことを発表しました。ベイジーンは特許付与後レビュー（PGR）の手続きにおいて本件に対する異議申し立てを行っていました。 2023年11月1日、Pharmacyclicsがベイジーンに対してBRUKINSA®（ザヌブルチニブ）に関する特許権侵害訴訟を提起したのを受け、ベイジーンはUSPTOに対し、「803号特許」の特定の請求項の有効性を争うPGRを申請しました。USPTOは2024年5月1日にベイジーンのPGR請求を承認しています。PharmacyclicsはUSPTOの最終書面決定に対し、審判請求することが...

SAN CARLOS, California--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una compañía global de oncología que planea cambiar su nombre por el de BeOne Medicines Ltd., anunció hoy que la Oficina de Patentes y Marcas Registradas de Estados Unidos (USPTO, por sus siglas en inglés) emitió una resolución final por escrito que invalida todas las reivindicaciones de Pharmacyclics LLC (Pharmacyclics) de la patente estadounidense n.º 11.672.803 (la patente ’803) que BeiGene impugn...

SAN CARLOS, California--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale che ha in programma di cambiare il proprio nome in BeOne Medicines Ltd., oggi ha annunciato che l'Ufficio brevetti e marchi degli Stati Uniti (USPTO) ha emesso una decisione scritta finale che invalida ogni rivendicazione del brevetto statunitense n. 11.672.803 (il brevetto '803) di Pharmacyclics LLC (Pharmacyclics) contestato da BeiGene nel corso di un procedimento di revi...